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OBJECTIVES: Cerner has developed the St John’s Sepsis Alert, an evidence-based 
real-time algorithm that alerts clinicians to the presence of the Systemic 
Immune Response Syndrome or sepsis. Using simulation, we estimated the 
Alert’s performance and determined the optimal cut-offs for ~17 included 
quantitative parameters (e.g., blood pressure). METHODS: We estimated the 
operating characteristics of the alert by applying its logic to 3 years of real-world 
data on adults from Cerner Health Facts, a time-stamped database extracted from 
electronic medical records. We evaluated the base-case and performed a 10,000-
iteration uncertainty analysis. Each run used a different set of thresholds, each 
drawn randomly from the range of reasonable values using a Latin hypercube 
sampling design under the assumption of an independently distributed joint 
beta distribution. Each run provided a point on the Receiver Operator 
Characteristic curve. We constructed an extended dominance curve from the 
resulting point cloud and determined the optimal values as those associated 
with that curve. RESULTS: Data from ~69,000 hospitalizations with a 5% 
incidence of sepsis were available. Using baseline values for the Alert, we 
estimated a Sensitivity of 56%, Specificity of 90%, Positive Predictive Value of 
22%, and Negative Predictive Value of 98%. The uncertainty analysis found that 
10 sets of cut-offs dominated all the others. The C-statistics for these ranged 
from 67% to 75%, Sensitivity from 39% to 73%, Specificity from 96% to 76%, PPV 
33% to 13%, NPV 95% to 98%, and the posterior probability of sepsis increased 
from 2.4- to 7-fold. The most accurate thresholds were not necessarily optimal 
for implementation; certain sets with only slightly lower C-statistics greatly 
decreased false positive rates. CONCLUSIONS: Simulation can usefully inform in 
the design of clinical algorithms prior to implementation. Examining a range of 
thresholds can identify statistical optimality and characterize trade-offs to 
deviating from it.  
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OBJECTIVES: The Dutch guideline for cancer rehabilitation recommends patients 
to engage in multicomponent interventions, i.e. several single interventions 
combined into a rehabilitation programme. To perform a health economic 
evaluation of this guideline, data on the cost-effectiveness of these 
multicomponent interventions is required. However, to date, the interventions´ 
(cost-)effectiveness is almost exclusively assessed for the single interventions, 
rather than for the multicomponent intervention, which challenges the health 
economic analysis of the multicomponent interventions. The objective of this 
study was to identify or develop a method that allows to deduct the cost-
effectiveness of multicomponent interventions from published data of the single 
interventions. METHODS: We searched the literature for articles offering a 
method or ideas for the development of a method for assessing the cost-
effectiveness of multicomponent interventions on the basis of data on the single 
interventions. The cost-effectiveness gap analysis method, which can be used for 
assessing the maximum cost of an intervention given a certain willingness-to-
pay, was identified as suitable and was further developed to allow assessing if a 
multidimensional programmes is cost-effective, based on the (cost-)effectiveness 
data of the single interventions. RESULTS: Cost-effectiveness gap analysis was 
identified in the literature as being a suitable method, with further refinement. 
We suggested to first calculate the costs of all interventions. Given the 
effectiveness of one intervention it is then possible to estimate how much 
additional effectiveness a second (or any subsequent) intervention would have to 
provide so that the multicomponent intervention remains cost-effective, given a 
range of ceiling ratios. Recommendations for methods for estimating the 
additional effect of subsequent interventions were deducted from the literature 
identified. CONCLUSIONS: We suggest estimating the cost-effectiveness of the 
combined interventions as recommended in clinical guidelines by performing a 
refined cost-effectiveness gap analysis method.  
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OBJECTIVES: Along with uncertainty around reimbursement decisions, one 
should determine the worth of additional research to reduce the probability of 
making wrong decisions. Value of information analysis (VOI) provides an explicit 
framework to inform future research. The objectives of this research were to 
assess published evidence of VOI and to evaluate its impact on decision making 
and research agendas. METHODS: A literature review was conducted in MEDLINE 
and EMBASE to collect studies with VOI applications published until November 
2012. Data extracted included study indication, year, country, sponsorship, type 
of VOI analysis, research impact and quality of the study. HTA guidelines of 
developed countries were checked and country experts were approached to 
discuss the relevance of VOI. RESULTS: One hundred studies with VOI 
applications were identified. Amongst these, cancer was the most popular 
indication (25%) and the majority had a UK perspective (49%). The number of 
publications gradually rose after 2005 but remained steady since 2009. Rarely, 
studies were sponsored by industry (8%). Expected value of perfect (parameter) 
information (EVP(P)I) was reported in 92% (59%) of the articles, respectively. Only 
12% of articles reported expected value of sample information (EVSI) and 4% 
reported expected value of perfect implementation (EVPIM). Finally, no actual 
implication on future research had been reported. Only the UK and Netherlands 
recommend the use of VOI in the HTA guideline. However VOI is not a formal 
requirement in the manufacturer/sponsor submission of evidence to NICE or 
CvZ. All experts reported lack of influence of VOI in research decision. 
CONCLUSIONS: The application of VOI to inform HTA and research is limited. 
Even in the UK and Netherlands, where VOI analysis is recommended in the HTA 
guidelines.  
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OBJECTIVES: We want to develop a parametric model to predict mortality for 
future patients with a disease that have specific demographic and clinical 
characteristics while considering patient trajectories over time for a set of 
biomarkers, which are critical predictors of disease progression. This is an 
important tool for many health economic projections. METHODS: In time-to-
event studies, longitudinal measures are collected for important disease 
progression biomarkers. Using only the last available value of these measures in 
survival models discards important information from the longitudinal evolution. 
We used data from a 3-year observational study to estimate the covariate 
coefficients in a Cox-proportional hazards model in the presence of time-
dependent biomarkers via SAS® PHREG. In addition, we applied a Weibull 
accelerated failure time model to estimate the scale/shape of a parametric 
survival distribution using SAS®LIFEREG, which, unlike PHREG, does not allow for 
direct incorporation of longitudinal measures. In developing the final prediction 
model, we combined the coefficients from PHREG and the scale/shape from 
LIFEREG to compute the probability of survival. RESULTS: By applying the 
Weibull model without considering patient trajectories over time, we predicted a 
3-year survival rate of 55.1%. However, the hybrid combination approach of the 
Cox/Weibull model, predicted a more accurate 3-year survival rate of 46.7%, 
which fell within the confidence bounds of the original observational study. 
CONCLUSIONS: Ignoring the additional variability of patient trajectories over 
time, when modeling survival, can lead to biased estimates. We have 
implemented a hybrid approach by which we incorporated the impact of time-
dependent biomarkers of the disease along with the scale/shape of a parametric 
survival distribution to more accurately project survival time in health economic 
modeling.  
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OBJECTIVES: It is not uncommon to have heterogeneous patient populations in 
clinical trials while lacking established biomarkers/factors to identify 
heterogeneity. In estimating average survival time, a critical component in 
economic models, extrapolation of limited trial data is often necessary and 
standard parametric survival models are regularly used without considering 
population heterogeneity. Our project was to introduce mixture modeling that 
incorporated population heterogeneity. METHODS: Heterogeneous survival data 
were simulated. Mixture models, besides standard survival models, were applied 
to address population heterogeneity via Bayesian inference, where clinical 
inputs (e.g., survival of one sub-population is longer than the other) can also be 
incorporated. The model fit was evaluated and the average survival was 
estimated. RESULTS: Two-hundred patient level survival data were simulated 
from a mixture of two exponentials with average survival of 3 (30% of patients) 
and 0.6 year respectively and overall average survival of 1.32 years. The 
simulation was run 100 times. For each dataset, Bayesian inference was based on 
10000 iterations after 1000 burn-in. In one exercise, the standard approach, 
including exponential, Weibull and lognormal models, and a mixture of two 
exponentials were applied. The mixture model provided a good fit per DIC and 
the estimated proportion was 0.372 (SD: 0.13). The estimates for average survival 
were compared across methods (true mean: 1.32; exponential: 1.238 [SD: 0.142], 
Weibull: 1.260 [SD: 0.151], lognormal: 1.760 [SD: 0.311]; exponential mixture: 1.311 
[SD: 0.178]). The extension to mixture models with different components 
(number or structure) could be implemented. CONCLUSIONS: The mixture 
modeling could potentially improve the estimates for average survival time in 
heterogeneous populations. Though this doesn’t apply in every situation, 
heterogeneity should be considered based on clinical inputs, and tools that 
address heterogeneity from both clinical and statistical perspectives should 
continue to be developed to support survival modeling.  
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OBJECTIVES: Technical, ethical, and practical reasons may hamper efforts to 
understand how survival rates of treated and untreated individuals change as a 
result of disease progression. This is a rather general problem that concerns 
communicable and non communicable diseases alike. In certain instances, the 
only available survival information refers to prevalent (as opposed to incident) 
cohorts, where individuals are randomly selected and enrolled irrespectively of 
